The drug combination should be a first line of treatment, UCLA researchers say.
The prominent cancer researcher is honored for his invention of the breast cancer drug Herceptin.
The system could help reduce errors in differentiating ductal carcinoma in situ, a noninvasive type of cancer, from breast atypia.
“This trial was unique because it looks at younger women who haven’t gone through menopause,” said Dr. Sara Hurvitz, the study’s lead author.
The driving force behind the development of Herceptin will split a $1 million prize from the Royal Swedish Academy of Sciences and the Sjöberg Foundation.
The six-year-long study about endocrine treatment is contrary to expectations.
Researchers found that lower activity of an enzyme that helps maintain cells’ health along with DNA damage were associated with worse cognitive performance, such as attention and motor skills.
Childhood trauma, depression linked to higher risk of longer-term fatigue in breast cancer survivors
The findings may help to offer better solutions for preventing and managing fatigue.
UCLA participates in #PinkLA, in which buildings throughout the city are illuminated for Breast Cancer Awareness Month.
The next step is to determine why the numbers are so low and find ways to increase those rates of testing.
UCLA Anderson’s Elisa Long, informed by personal experience, parses data to help those mulling mastectomy and gynecological surgeries to reduce cancer risk.
Three fact sheets recommend that legislators enact changes to help patients and survivors — particularly low-income women — who face serious obstacles to care.
UCLA’s Christopher Childers says the relevant genetic mutations can be easily detected through blood or saliva analysis.
UCLA researchers found that with estrogen therapy for menopause, taking a pill versus wearing a patch on one’s skin doesn’t affect risk or benefit.
UCLA study shows that slow-moving meditation practice works just as well as talk therapy, and better than medication.
Customized treatment plans are particularly important for lower-income women, who tend to have less access to high-quality health care.
Every year as Californians file their state income taxes, they have an opportunity to help University of California researchers and others in the fight against cancer.
California State Senate will discuss barriers, such as difficult-to-navigate health system, inadequate insurance, and cultural misconceptions, as well as possible solutions Jan. 12.
Drug combination therapy for estrogen-receptor–positive breast cancer passes critical step for worldwide approval
UCLA study showed positive results for palbociclib when used in combination with letrozole and without the side effects of traditional chemotherapy.
Though the test reduces the number of women undergoing radiation, researchers say doctors and policy makers should further discuss the value of using Oncotype DX DCIS.
Using big data, scientists discover biomarkers that could help give cancer patients better survival estimates
The technique, developed by a team led by UCLA professor Yi Xing, is an innovative way of using biomedical big data to achieve precision medicine.
Widely used class of chemotherapy drugs does not lead to cognitive decline for women with breast cancer
An earlier study had suggested that a class of drugs called anthracyclines might increase the risk for neuropsychological issues and cognitive difficulties.
The findings could be an important step toward personalized medicine for women with the disease, said UCLA’s Dr. Patricia Ganz.
Wireless mobile devices developed at UCLA are transforming the face of health care and ushering in a new kind of patient/physician partnership.
Other diagnostic tools may be more efficient and cost-effective for the general population, although genetic screening remains valuable for women in groups known to carry certain genetic mutations.